FDA Clears Phase 2 Trial of Lorundrostat for Obstructive Sleep Apnea and Hypertension

The phase 2, placebo-controlled, crossover trial will test whether 50 mg once daily lorundrostat may relieve the severity of upper airway obstruction and reduce nocturnal hypertension.:

Source: Neurology Read More